Superluminal Medicines

Executive Summary

Superluminal Medicines is a preclinical-stage biotechnology company headquartered in Cambridge, MA, leveraging a proprietary structure-based drug design platform to develop small molecule therapeutics for challenging targets in neuroscience. The company focuses on neurodegenerative and psychiatric disorders with high unmet medical need, including Alzheimer's disease, Parkinson's disease, and depression. Founded in 2021, Superluminal has raised $153 million in funding to advance its pipeline of precision medicines. Its approach integrates computational chemistry, structural biology, and machine learning to design novel compounds that modulate disease-relevant protein targets with high specificity and brain penetration. The company's mission is to transform the treatment landscape for brain diseases by delivering first-in-class and best-in-class oral small molecules.

Upcoming Catalysts (preview)

• Q3 2026Presentation of preclinical in vivo efficacy data for lead neurodegenerative program at a major neuroscience conference70% success
• Q3 2026Announcement of Series B financing round led by top-tier life sciences investors80% success
• Q4 2026Selection of development candidate for psychiatric program and initiation of IND-enabling studies60% success